Published on: Feb 1, 2017 | by Trevor Hoey
Creso Pharma (ASX: CPH) has announced that it has expanded its Australian presence, signing its first Australian letter of intent with Western Australian-based pharmacy, Health House International, for the import and sale of cannabis products in the Australian market.
CPH has established itself as a leader in cannabidiol (CBD) innovation and the group develops cannabis and hemp derived therapeutic grade CBD nutraceuticals and medical cannabis products with wide patient reach for human and animal health.
Consequently, this agreement is a significant development for the company as it opens up an additional revenue stream and expands its presence in a familiar market where there is political support for the use of cannabis related products in treating medical conditions.
Further demonstrates the benefits of CPH’s vertically integrated model
Under the terms